Skip to main content

2B-Trans™ Technology: Targeted Drug Delivery Across the Blood-Brain Barrier

  • Protocol
Drug Delivery Systems

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 437))

Abstract

Drug delivery across the blood–brain barrier (BBB) is a major obstacle for the development of effective treatments of many central nervous system disorders. Sophisticated cell culture models of the BBB have helped us to identify, characterize, and validate a novel targeted drug delivery technology, designated 2B-Trans, for the receptor-mediated uptake and transport of drugs across the BBB. This paper describes in great detail how such a BBB cell culture model should be prepared and handled, and applied for the use of targeted drug delivery across the BBB.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. 1. de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood–brain barrier. Annu Rev Pharmacol Toxicol 2003;43:629–56.

    Article  CAS  Google Scholar 

  2. 2. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007;47:9.1–9.33.

    Article  Google Scholar 

  3. 3. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood–brain barrier. Expert Opin Drug Deliv 2005;2(2):299–309.

    Article  CAS  Google Scholar 

  4. 4. Gaillard PJ, Brink A, de Boer AG. Diphtheria-toxin receptor-targeted brain drug delivery. Int Congress Series 2005;1277(11):185–98.

    Article  CAS  Google Scholar 

  5. 5. Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD. Establishment and functional characterization of an in vitro model of the blood–brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci 2001;12(3):215–22.

    Article  CAS  Google Scholar 

  6. 6. Franke H, Galla HJ, Beuckmann CT. An improved low-permeability in vitro-model of the blood–brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res 1999;818(1):65–71.

    Article  CAS  Google Scholar 

  7. 7. Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood–brain barrier. Pharm Res 2000;17(10):1198–205.

    Article  CAS  Google Scholar 

  8. 8. van der Sandt IC, Gaillard PJ, Voorwinden HH, de Boer AG, Breimer DD. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood–brain barrier. Pharm Res 2001;18(5):587–92.

    Article  CAS  Google Scholar 

  9. 9. Gaillard PJ, de Boer AB, Breimer DD. Pharmacological investigations on lipopolysaccharide-induced permeability changes in the blood–brain barrier in vitro. Microvasc Res 2003;65(1):24–31.

    Article  CAS  Google Scholar 

  10. 10. Roux F, Couraud PO. Rat brain endothelial cell lines for the study of blood–brain barrier permeability and transport functions. Cell Mol Neurobiol 2005;25(1):41–58.

    Article  Google Scholar 

  11. 11. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005;19(13):1872–4.

    CAS  Google Scholar 

  12. 12. Gaillard PJ, de Boer AG. Relationship between permeability status of the blood–brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci 2000;12(2):95–102.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

Part of the work described in this paper was supported by a grant from ZonMw-Dierproeven Begrensd (3170.0057). The authors would like to acknowledge Drs. Heleen Voorwinden, Dr. Corine Visser, and Drs. Arjen Brink for their excellent experimental contributions to the data presented in this paper.

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science + Business Media, LLC

About this protocol

Cite this protocol

Gaillard, P.J., de Boer, A.G. (2008). 2B-Trans™ Technology: Targeted Drug Delivery Across the Blood-Brain Barrier. In: Jain, K.K. (eds) Drug Delivery Systems. Methods in Molecular Biology™, vol 437. Humana Press. https://doi.org/10.1007/978-1-59745-210-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-210-6_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-891-1

  • Online ISBN: 978-1-59745-210-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics